Drug Trial Radar · NCT06109818
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Jan 4, 2024
Primary completion
Aug 5, 2024
Study completion Sep 18, 2024
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with moderate to severe plaque psoriasis.
Conditions
- Moderate to Severe Plaque Psoriasis
Interventions
ICP-488 TabletsDrug
ICP-488 will be administered as tablet
ICP-488 PlaceboDrug
ICP-488 Placebo will be administered as tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12.Time frame: Baseline up to Week 12
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
Guangdong Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China
Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
The Affiliated Hospital of Chengde Medical College
Chengde, Hebei, China
The first hospital of hebei medical university
Shijiazhuang, Hebei, China
The Second Affiliated Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Nanyang city first People's Hospital
Nanyang, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
Shiyan City People's Hospital
Shiyan, Hubei, China
Wuhan University People's Hospital
Wuhan, Hubei, China
Wuhan No.1 hospital
Wuhan, Hubei, China
Xiangya hospital central south university
Changsha, Hunan, China
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Changzhou First People's Hospital
Changzhou, Jiangsu, China
Lianyungang First People's Hospital
Lianyungang, Jiangsu, China
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of medical Sciences, Peking Union Medical College
Nanjing, Jiangsu, China
First Hospital of Jilin University
Changchun, Jilin, China
Mei he kou central hospital
Meihekou, Jilin, China
Central Hospital affiliated to shandong first medical unversity
Jinan, Shandong, China
Shanghai Dermatology Hospital
Shanghai, Shanghai Municipality, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Chengdu Second People's Hospital
Chengdu, Sichuan, China
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
The First Hospital of Jiaxing
Jiaxing, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.